The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

Methods: Members of the Hypertrophic Cardiomyopathy Association ... demographic and self-reported clinical information, and types and triggers of symptoms. Respondents reported physical and ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

Aficamten is a small molecule cardiac myosin inhibitor designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle.

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden ...

PDUFA Target Action Date Set for September 26, 2025SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted the company’s New ...

The S3 heart sound is essentially blood rushing into a specific chamber. Learn how this sound correlates to congestive heart ...

Sudden cardiac arrest and death occur among competitive and recreational athletes across the entire spectrum of age, sex, and ...

Seven of 11 patients with asymmetric hypertrophic cardiomyopathy, whose evaluation included angiography of the left ventricle were found to have a distinctive angiographic abnormality of the ...